Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma - LARVOL DELTA

Korean botulinum toxins. (PubMed, J Neural Transm (Vienna)) - "These are PrabotulinumtoxinA (Daewoong/Evolus) and LetibotulinumtoxinA (Hugel/Croma Pharma). There are 12 Class 2 drugs from 10 Korean manufacturers registered in Korea for export and domestic use, including Neuronox®, the first Korean BT drug registered in 2006, NivobotulinumtoxinA/Innotox®, the world-wide first liquid BT type A preparation and Coretox®, the world-wide second BT drug without complexing proteins...5 Korean manufacturers have 5 drug projects in Korea in advanced development phases. With this, Korea is now the country with the worldwide largest number of BT manufacturers and BT drugs."

Journal

A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A (clinicaltrials.gov) - P=N/A | N=20 | Completed | Sponsor: Yuvell

New trial

Efficacy and Safety of LetibotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Systematic Review and Meta-Analysis of RCTs. (PubMed, Aesthetic Plast Surg) - "LetibotulinumtoxinA-wlbg is an efficacious and well-tolerated treatment for moderate-to-severe glabellar lines. The therapeutic effect is durable, with statistically significant efficacy maintained at 12 and 16 weeks post-treatment. Treatment results in a significant improvement in patients' psychological well-being related to their facial appearance. The safety profile is favorable, with no statistically significant increase in the risk of serious or non-serious adverse events compared to placebo. Further research, including direct head-to-head trials, is warranted to establish its comparative effectiveness."

Journal • Retrospective data • Review • Aesthetic Medicine

Pilot Retrospective Evaluation of a Balancing and Optimizing Injection Pattern for the Frontalis Muscle Using LetibotulinumtoxinA. (PubMed, Toxins (Basel)) - "These findings suggest that this structured injection approach may offer a consistent method for addressing forehead lines; however, the results should be interpreted within the limitations of a small, uncontrolled retrospective series. Prospective controlled studies with larger populations are needed to further validate the technique."

Journal • Retrospective data

Excipient substitution in botulinum toxin type A formulations: Insights from multi-scale in silico modelling. (PubMed, J Pharm Sci) - "Reformulated PRABO and LETYBO with trehalose-HSA achieved the longest durations (186 ± 8 and 184 ± 9 days), followed by INCO (176 ± 7), ONA (170 ± 8), DAXI (167 ± 10), and ABO (160 ± 7). Reconstitution with 0.5 mL per 100 units minimized spread (1.22 ± 0.04 mm) and maximized persistence (188 ± 9 days, p < 0.01 vs 2.5 mL). Across molecular, mesoscopic, and tissue levels, trehalose-HSA consistently provided superior stability, aggregation resistance, and duration, offering a rational basis for next-generation BoNT/A formulations."

Journal

Hypersensitivity Reactions Associated With Aesthetic Botulinum Toxin A Injections: A Case Series. (PubMed, Cureus) - "In the first case, a 44-year-old woman developed severe angioedema after resuming abobotulinumtoxinA injections following a 12-month pause. Subsequent intradermal tests with onabotulinumtoxinA and incobotulinumtoxinA produced localized reactions, suggesting hypersensitivity to a shared component across formulations, possibly the 150 kDa BoNT/A neurotoxin itself. In the second case, a 38-year-old woman experienced delayed erythema and swelling after letibotulinumtoxinA treatment but tolerated subsequent incobotulinumtoxinA injections, suggesting possible reactivity to complexing proteins or other non-core components rather than the neurotoxin. In the third case, a 50-year-old woman developed systemic symptoms and localized swelling after prabotulinumtoxinA administration, consistent with a delayed-type hypersensitivity reaction...Overall, this case series underscores the importance of clinical vigilance, appropriate patient selection, and awareness of rare but meaningful..."

Journal • Aesthetic Medicine • Cardiovascular • Dermatology • Immunology

Real-World Outcomes of a Novel Botulinum Toxin A for Upper Face Aesthetics: Insights From Routine Clinical Practice. (PubMed, Aesthet Surg J Open Forum) - "Comprehensive upper-face treatment with letibotulinumtoxinA showed meaningful, sustained aesthetic improvement with good tolerability. These findings support further research in larger populations."

Journal • Real-world evidence

High-resolution mass spectrometry and enzyme-linked immunosorbent assay for detection of residual botulinum concentrations in a mouse model of botulism. (PubMed, Leg Med (Tokyo)) - "Our research indicates that under specific sample preparation, chromatographic separation, and untargeted detection conditions, mass spectrometry may not be effective for detecting Botulinum toxin at concentrations below the ng/ml level. The study demonstrates that ELISA is a sensitive and practical alternative for early detection. Positive results can be detected within 2 h of poisoning, especially when taken from muscle tissue."

Journal • Preclinical • CNS Disorders • Dystonia • Movement Disorders • Muscle Spasticity

Computational Model-Informed Comparative Evaluation of Botulinum Toxin A Formulations: A 20-Year Simulation of Onset, Diffusion, Duration, and Immunogenicity. (PubMed, Toxicon) - "LetibotulinumtoxinA and PrabotulinumtoxinA predicted the most balanced profiles, combining high efficacy (mean peak strain reduction 72% and 68%, respectively), rapid onset (2.7-3.1 days), and minimal predicted neutralizing antibody incidence over 20 years (0.4-0.6%). DaxibotulinumtoxinA showed the longest modelled duration of effect (median 142 days), whereas AbobotulinumtoxinA and Relatox exhibited broader diffusion and higher immunogenicity risk...These simulations align closely with available empirical data and suggest that formulation-specific differences in protein structure, diffusion behaviour, and antigenicity may contribute to observed clinical variability. Model-informed comparative analysis can complement real-world and prospective studies to optimize product selection and dosing strategies in aesthetic and therapeutic applications."

Clinical • Journal

Evaluation of the diffusion characteristics of LetibotulinumtoxinA in comparison to Ona- and AbobotulinumtoxinA in a double-blind, randomized split-face study (EADV 2025) - "Therefore, the diffusion characteristics of LetibotulinumtoxinA (Leti-BoNTA), the market leader in South Korea, was compared with OnabotulinumtoxinA (Ona-BoNTA) and AbobotulinumtoxinA (Abo-BoNTA) in a randomized, double-blind, intra- individual split-face comparison. Leti-BoNTA exhibits precise and predictable diffusion while achieving the same clinical efficacy as Ona- and Abo- BoNTA4. Due to the significant differences in diffusion characteristics, treatment protocols should take product- specific behaviour into account, especially when changing formulations. Selection of the appropriate formulation is critical, as diffusion properties can influence therapeutic outcomes."

Clinical • Aesthetic Medicine • Dermatology

A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A. (PubMed, Dermatol Ther (Heidelb)) - "Intradermal injection of BoNT/A appears to elicit a stronger immunogenic response than intramuscular administration, although antibody levels did not reach clinically significant thresholds. These findings underscore the importance of injection technique and interval planning to mitigate immunogenicity. Given the widespread use of intradermal techniques in aesthetic practice, this study provides important clinical insight into optimizing BoNT/A administration."

Journal

A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles (clinicaltrials.gov) - P4 | N=20 | Completed | Sponsor: Yonsei University

New P4 trial

Diffusion Characteristics of LetibotulinumtoxinA, OnabotulinumtoxinA, and AbobotulinumtoxinA and its Impact on Muscle Relaxation: A Randomized Split-Face Clinical Trial. (PubMed, Dermatol Ther (Heidelb)) - "Leti-BoNTA provides wrinkle reduction with a more limited diffusion, as assessed with the Minor's starch-iodine test. Its precise action in this trial implies to be a viable option when controlled spread is essential."

Journal • Aesthetic Medicine

Compensatory Masseteric Bulging: A Novel Observation and Its Implications for Botulinum Neurotoxin Injection Techniques. (PubMed, J Cosmet Dermatol) - "Compensatory bulging underscores the need for holistic treatment addressing the entire muscle. Layered injections, guided by ultrasound and tailored dosing, mitigate asymmetry risks. Clinicians must adopt comprehensive strategies, integrating anatomical insights and advanced imaging, to optimize aesthetic outcomes in masseter hypertrophy management."

Journal

Cross induction of anti-complexing antibodies in botulinum treatment patients injected with botulinum toxin containing complexing proteins (AAD 2025) - "One-hundred participants were divided into 5 subgroups for using 5 types of BoNT/A (incobotulinumtoxinA(IncoA), onabotulinumtoxinA(OnaA), abobotulinumtoxinA(AboA), letibotulinumtoxinA(LetiA), and prabotulinumtoxinA(ProboA). AboA which has difference molecular weight can induce only some type of antibody against CPs. IncoA which do not contain complexing protein is not induced antibody against CPs."

Clinical

Hugel wins UAE approval for botulinum toxin Botulax (PRNewswire) - "Hugel Inc...said on Wednesday it received approval for its botulinum toxin Botulax with aesthetic and therapeutic applications from the United Arab Emirates (UAE) on January 20, achieving a significant milestone for the company's global expansion...The approval of Botulax in 50IU, 100IU, and 200IU covers five aesthetic and medical indications: eyelid spasm; crow's feet; glabellar lines; upper extremity muscle spasticity after stroke; and cerebral palsy adduction deformity in children."

Approval • CNS Disorders • Dermatology • Muscle Spasticity

A Novel Technique for the Topical Application of Botulinum Neurotoxin A to the Nasal Mucosa in Reducing Rhinitis Symptoms. (PubMed, Cureus) - "Topical application of BTA on the nasal mucosa can be considered an effective therapeutic option in patients with persistent AR and idiopathic rhinitis. In comparison with injection techniques, BTA mucosal spray is effective at reducing persistent symptoms while minimizing the risk of pain and inadvertent systemic injection, and is able to promote contact with a wider mucosal area. Furthermore, it is easy to perform and is more tolerable for the patient. The authors present recommended concentrations, doses, and techniques."

Journal • Allergic Rhinitis • Immunology • Inflammation • Pain

Consensus Recommendations for Treatment of the Upper Face With LetibotulinumtoxinA. (PubMed, Plast Aesthet Nurs (Phila)) - "The panelists provided recommendations for treating forehead horizontal lines, glabellar frown lines, and lateral canthal lines. The guidelines developed by the panel will support clinical practitioners of all skill levels in providing safe and effective aesthetic treatments of the forehead, glabellar complex, and lateral canthal lines with letibotulinumtoxinA."

Journal • Aesthetic Medicine

Investigating the impact of botulinum toxin type a on the migration of normal human dermal fibroblasts: An in vitro wound healing assay. (PubMed, J Cosmet Dermatol) - "Different types and dilutions of BoNT-A demonstrated variable inhibitory effects on NHDF migration in vitro. The selection of BoNT-A formulation may significantly impact the clinical outcome of scar prevention related to fibroblast migration."

Journal • Preclinical • Fibrosis • Immunology

Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles. (PubMed, Dermatol Ther (Heidelb)) - "The structural differences among BoNT/A brands did not significantly affect the longevity and efficacy of bite force reduction and wrinkle treatment."

Journal • Aesthetic Medicine

Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females 35 to 50 Years of Age: Post Hoc Analyses of the Phase 3 Clinical Study Data. (PubMed, Aesthet Surg J Open Forum) - "Response rates remained higher up to Week 16. The treatment demonstrated efficacy and safety in treating vertical glabellar lines in this patient group."

Journal • P3 data • Retrospective data

LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials. (PubMed, Dermatol Surg) - "LetibotulinumtoxinA significantly improved the psychosocial burden associated with glabellar lines across all trials. Treated subjects experienced improved quality of life, younger perceived age, and satisfaction with treatment outcome."

Journal • P3 data

Commentary on: Use of LetibotulinumtoxinA for Aesthetic Treatment of Asians: A Consensus. (PubMed, Aesthet Surg J) - No abstract available

Journal • Aesthetic Medicine

"@Channel7 why are you advertising new cosmetic injectable schedule 4 medications on your evening news program as news articles? Your segment on Letybo letibotulinumtoxinA was not news but a bald faced drug advertisement. @TGAgovau @acccgovau" (@tev_mek)

The effect of botulinum toxin type A on normal human dermal fibroblasts in an in vitro wound healing assay (WCD 2023) - "Then, the scratched NHDF monolayer was treated with varying concentrations of 10, 20, 25, 40, 50 and 100 units/milliliter (U/ml) of onabotulinumtoxinA (ONA), letibotulinumtoxinA (LETI), prabotulinumtoxinA (PRABO) and incobotulinumtoxinA (INCO) and 33, 50, 66, 71, 100, 150, 300, and 500 U/ml of abobotulinumtoxinA (ABO). Different types and dilution of BoNT-A provided variable inhibitory effects on fibroblast migration in vitro. The selection of BoNT-A used may influence the clinical outcome for scar prevention"

Late-breaking abstract • Preclinical • Fibrosis • Immunology